Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by James E. Udelson
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
Despite raising plasma cGMP, tovinontrine failed to lower NT-proBNP in patients with heart failure with preserved ejection fraction (HFpEF) at the highest dose.1 These data from the Cycle-2-PEF trial were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona, by James Udelson, MD, the chief of the division of cardiology at Tufts Medical Center.1 “We know that PDE9 is upregulated in heart failure, and in prior human biopsy studies and...
Tovinontrine Reduces NT-proBNP in HFrEF, May Have Greater Benefit at Smaller Doses
Tovinontrine, an investigative oral phosphodiesterase 9 (PDE9) inhibitor, has successfully reduced NT-proBNP in patients with heart failure with reduced ejection fraction (HFrEF), based on results from the phase 2 Cycle-1-REF trial.1 These data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona, by James Udelson, MD, chief of the division of cardiology at Tufts Medical Center.
124 I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis : The REVEAL Nonrandomized Clinical Trial
|
124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial Supplement 1. Supplement 2. Statistical Analysis Plan Supplement 3. eTable 1. Inclusion and Exclusion Criteria eTable 2. Demographic and Clinical Characteristics of the Patients at Baseline by Disease Status and ATTR and AL Subtypes eTable 3. Summary of Inter-Reader Agreement eTable 4. Treatment-Emergent Adverse Events eFigure 1.
By Sharmila Dorbala, Mathew S. Maurer, Sarah Cuddy, Omar F. AbouEzzeddine, Marcelo Di Carli, Vasken Dilsizian, Angela Dispenzieri, Cesia Gallegos-Kattan, Spencer Guthrie, Brian Mangal, Mazen Hanna, Michel G. Khouri, Saurabh Malhotra, Joshua Mitchell, Ravi Narra, Cesare Orlandi, Julie Rosenthal, Frederick L. Ruberg, Dia A. Smiley, Brett W. Sperry, James E. Udelson, Richard L. Weinberg, Jonathan Wall Verified, Ahmad Masri, Mouaz H. Al-Mallah, Kevin Alexander, Sabahat Bokhari, Panithaya Chareonthaitawee, Philip Kuo, Wesley T. O'Neal, Ashutosh D Wechalekar, Benjamin Rainer Auer, Marie Foley Kijewski, Olivier Clerc
|
JAMA: Journal of the American Medical Association
Verified
Fluid Management of Acute Heart Failure With the Reprieve System: The Randomized Controlled FASTR Trial
Methods FASTR (Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System [DMS]; NCT05174312) was a randomized, prospective, open-label pilot trial. Its primary goal was optimizing the Reprieve System algorithm and providing proof-of-concept that the Reprieve System can facilitate rapid and safe decongestion compared with a control strategy of optimal diuretic therapy (ODT).
Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial
JACC Journals › JACC › Archives › Vol.
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure:
Methods This trial was designed as a phase 2 randomized, double-blind, placebo-controlled, parallel group clinical trial. Eligible patients with HFrEF were randomized to either CRD-740 or placebo in a 2:1 ratio. Randomization was stratified on the baseline use or nonuse of sacubitril/valsartan. As shown in the trial design schematic in Supplemental Figure 1, patients started period 1 at a dose of CRD-740 10 mg orally twice daily or matching placebo and remained on that dosage for 2 weeks.
What Counts for Worsening Heart Failure Events
What Counts for Worsening Heart Failure Events Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction Jonathan W. Cunningham, MD, MPH; Safia Chatur, MD; Brian L. Claggett, PhD; Muthiah Vaduganathan, MD, MPH; Akshay S. Desai, MD, MPH; Pardeep S. Jhund, MD, PhD; Guillermo Llamas Esperón, MD; Carolyn S. P.
THT 2025: FASTR: Fluid Management of Acute Decompensated Heart Failure with Reprieve Decongestion Management System
THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the Reprieve DMS.
Interpreting Health Status Measures in Patients With Heart Failure-What Counts
Interpreting Health Status Measures in Patients With Heart Failure—What Counts Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire Mohammad Abdel Jawad, MD; Philip G. Jones, MS; Suzanne V. Arnold, MD, MHA; David J. Cohen, MD, MSc; Charles F. Sherrod, MD; Mirza S. Khan, MD; Nobuhiro Ikemura, MD, PhD; Paul S. Chan, MD, MSc; John A.
Heart Failure With Preserved Ejection Fraction-A Role for Invasive Hemodynamics
Heart Failure With Preserved Ejection Fraction—A Role for Invasive Hemodynamics Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation Jwan A. Naser, MBBS; Tomonari Harada, MD, PhD; Yogesh N. Reddy, MBBS; Sorin V. Pislaru, MD, PhD; Hector I. Michelena, MD; Christopher G. Scott, MS; Austin M. Kennedy, BS; Patricia A. Pellikka, MD; Vuyisile T. Nkomo, MD, MPH; Mackram F. Eleid, MD; Barry A.
Assessment of Myocardial Viability in Ischemic Cardiomyopathy
Assessment of Myocardial Viability in Ischemic Cardiomyopathy—Scarred by the Data but Still Alive Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction Divaka Perera, MA, MD; Matthew Ryan, PhD; Holly P. Morgan, MBBCh; John P. Greenwood, PhD; Mark C. Petrie, MD; Matthew Dodd, MSc; Roshan Weerackody, PhD; Peter D.
No-Implant Interatrial Shunt for HFpEF: 6-Month Outcomes From Multicenter Pilot Feasibility Studies
References 1. "Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC Study Community Surveillance". Circulation . 2018;138:12-24. 2. "Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle". N Engl J Med . 2004;350:1953-1959. 3. "Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap". Circulation . 2016;134:73-90. 4.
Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: 50 Years On and Time for a Relook
Originally publishedhttps://doi.org/10.1161/CIRCULATIONAHA.121.058740Circulation. 2022;146:503–505 Footnotes References 1. Menees DS, Peterson ED, Wang Y, Curtis JP, Messenger JC, Rumsfeld JS, Gurm HS . Door-to-balloon time and mortality among patients undergoing primary PCI.N Engl J Med. 2013; 369:901–909. doi: 10.1056/NEJMoa1208200CrossrefMedlineGoogle Scholar 2. Maroko PR, Libby P, Sobel BE, Bloor CM, Sybers HD, Shell WE, Covell JW, Braunwald E .
AVANTI: Could a 'Vaptan' Replace Loop Diuretics in Acute HF?
This transcript has been edited for clarity. Ileana L. Piña, MD, MPH: Hello. This is Ileana Piña, professor of medicine at Central Michigan University and adjunct professor at Case Western Reserve. This is my blog. Today I am talking to you during the European Society of Cardiology (ESC) meeting, which is always an exciting time where we hear about a lot of new trials and new ideas.
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial | Cardiology | JAMA | JAMA Network
Key Points Question What is the effect of praliciguat, a soluble guanylate cyclase stimulator, on functional capacity in patients with heart failure with preserved ejection fraction? Findings In this randomized clinical trial that included 196 patients, there was no significant difference in the change in peak rate of oxygen consumption from baseline to week 12 in the placebo group compared with the 40-mg praliciguat group (0.04 vs −0.26 mL/kg/min).
Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease
Journal of the American College of Cardiology Original Investigation Jamshid Maddahi, Joel Lazewatsky, James E. Udelson, Daniel S. Berman, Rob S.B. Beanlands, Gary V. Heller, Timothy M. Bateman, Juhani Knuuti and Cesare Orlandi This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article.
Return to Play for Athletes After Coronavirus Disease 2019 Infection
As the coronavirus disease 2019 (COVID-19) pandemic began to evolve, case reports suggested that a clinical syndrome consistent with inflammatory myocarditis could occur as the underlying mechanism for the oft-seen elevations in biomarkers of myocardial injury and stress.1 However, as data have progressed, a picture has emerged from autopsy studies of myocardial involvement with viral infection and a cytokine response, but less often inflammatory cell infiltrate consistent with myocarditis.2...
Heart Failure Highlights From the 2020 ACC Virtual Meeting
Because of ongoing concerns about coronavirus, the 2020 American College of Cardiology annual meeting was held virtually. Dr James Udelson reviewed key abstracts in heart failure. The VICTORIA trial studied the efficacy of vericiguat in over 5000 heart failure patients with reduced ejection fraction. The study found that the agent reduced hospitalization or death due to heart failure over 11 months by 10% in patients with high risk for either outcome.
Heart Failure With Improved Ejection Fraction
Among patients with heart failure with reduced ejection fraction, investigators have repeatedly identified a subgroup whose left ventricular ejection fraction and structural remodeling can improve to normal or nearly normal levels with or without medical therapy. This subgroup of patients with “heart failure with improved ejection fraction” has distinct clinical characteristics and a more favorable prognosis compared with patients who continue to have reduced ejection fraction.
Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain
Introduction Editorial, see p 2333 Evaluation of chest pain is a fundamental element of cardiology patient care. On a daily basis, many physicians experience the clinical pressures to accurately rule out obstructive coronary artery disease (CAD) or myocardial ischemia as a cause of chest pain, while limiting the performance of unnecessary diagnostic testing.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with James E.
Contact James E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack